| Literature DB >> 34083044 |
Mohammad Mahmoudi Gomari1, Marziye Farsimadan2, Neda Rostami3, Zahra Mahmoudi1, Mahmood Fadaie4, Ibrahim Farhani5, Parastoo Tarighi6.
Abstract
Among cell surface markers, CD44 is considered the main marker for identifying and isolating the cancer stem cells (CSCs) among other cells and has attracted significant attention in a variety of research areas. Many studies have shown the essential roles of CD44 in initiation, metastasis, and tumorigenesis in different types of cancer; however, the validity of CD44 as a therapeutic or diagnostic target has not been fully confirmed in some other studies. Whereas the association of specific single nucleotide polymorphisms (SNPs) in the CD44 gene and related variants with cancer risk have been observed in clinical investigations, the significance of these findings remains controversial. Here, we aimed to provide an up-to-date overview of recent studies on the association of CD44 polymorphisms and its variants with different kinds of cancer to determine whether or not it can be used as an appropriate candidate for cancer tracking.Entities:
Keywords: CD44; Cancer marker; Cancer prognosis; Single nucleotide polymorphism
Year: 2021 PMID: 34083044 DOI: 10.1016/j.mrrev.2021.108374
Source DB: PubMed Journal: Mutat Res ISSN: 0027-5107 Impact factor: 2.433